Vicore Pharma Holding AB
NASDAQ:VCREMedical - Pharmaceuticals
Healthcare
$9.90 -1.66%
-$0.24 today
- Market cap
- $279.65M
- Beta
- 0.15
Volume 0.00M
Average 0.26M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$375.74M
FY 2025 · Annual
Investing Cash Flow
-$600.51M
FY 2025 · Annual
Financing Cash Flow
$430.54M
FY 2025 · Annual
-48.4% YoYCash Flow Statement
SEK
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.78M) | (290.73M) | (321.51M) | (194.19M) | (452.39M) |
| Depreciation & Amortization | 397.75K | 3.61M | 3.42M | 2.24M | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | (172.79K) | 0 | 0 | 0 | 0 |
| Change in Working Capital | (37.59K) | (20.94M) | (10.65M) | (1.84M) | 40.81M |
| Accounts Receivables | (37.59K) | (1.6M) | (4.28M) | (35.6M) | (3.08M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 0 | (19.34M) | (6.36M) | 33.77M | 43.89M |
| Other Non-Cash Items | (231.23M) | 8.13M | 79.15M | 28.84M | 35.84M |
| Operating Cash Flow | (263.82M) | (299.92M) | (249.58M) | (164.95M) | (375.74M) |
| Capital Expenditures | 0 | (3M) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (76.61M) | 0 | (199.04M) | (64.81M) | (983.95M) |
| Sales of Investments | 69.64M | 77M | 54.58M | 213.85M | 383.45M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (6.96M) | 74M | (144.46M) | 149.04M | (600.51M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 316.8M | 200M | 500.41M | 882.14M | 455.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (237.78K) | (12.96M) | (29.55M) | (48.08M) | (24.55M) |
| Financing Cash Flow | 316.56M | 187.04M | 470.86M | 834.06M | 430.54M |
| Effect of Forex Changes | (26.64M) | 1.48M | 0 | 4.23M | (32.16M) |
| Net Change in Cash | 2.3M | (37.4M) | 76.82M | 822.38M | (577.85M) |
| Free Cash Flow | (263.82M) | (302.92M) | (249.58M) | (164.95M) | (375.74M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$452.4M
+ D&A$0
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$40.8M
+ Other Non-Cash$35.8M
= Operating Cash Flow-$375.7M
- Capex$0
= Free Cash Flow-$375.7M
Analysis
FY2025 free cash flow is -$375.7M. FCF conversion is 83.1% of net income. Operating cash flow was -$375.7M, with capex of $0. The largest bridge item is Working Capital at $40.8M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 5, 2026 | |
| 6-K | 6-K filing | Nov 3, 2026 | |
| 6-K | 6-K filing | Oct 22, 2026 | |
| SC 13G | SC 13G filing | Oct 13, 2026 | |
| 6-K | 6-K filing | Sep 30, 2026 |
Does VCRE generate free cash flow?
Vicore Pharma Holding AB (VCRE) generated -$375.74M of free cash flow in fiscal 2025.
How much operating cash flow does VCRE produce?
Operating cash flow was -$375.74M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.